



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6,
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,
Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000

E: investorrelations@viyash.com

Website: www.viyash.com

CIN: L99999TS1985PLC196357

June 25, 2026

To,

BSE Limited

Corporate Relationship Department

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai – 400 001

National Stock Exchange of India Limited

Listing Department

Exchange Plaza, Bandra-Kurla Complex,

Bandra (East),

Mumbai – 400 051

Scrip code: 512529

Symbol: VIYASH

Subject: Submission of Investor Day presentation

Dear Sir/ Madam,

Pursuant to our intimation dated June 17, 2026, and in accordance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the presentation to be made at “Viyash Investor Day – 2026”, scheduled for today i.e. June 25, 2026, at Mumbai.

The aforesaid presentation is also being made available on the website of the Company at: www.viyash.com

You are requested to take the same on record.

Yours faithfully,

For Viyash Scientific Limited

(Formerly Sequent Scientific Limited)

Yoshita Vora

Company Secretary & Compliance Officer

Encl.



Viyash Scientific

INVESTOR DAY

VIYASH MANAGEMENT TEAM

June 2026

Section 01 ▶ **Welcome**

Section 02 ▶ **Our journey**

Section 03 ▶ **Our strengths**

Section 04 ▶ **Business snapshot**

Section 05 ▶ **Growth drivers**

Section 06 ▶ **Our aspiration**



1

WELCOME

About our MD & CEO



Dr. Haribabu Bodepudi

MD & Group CEO

- Dr. Haribabu Bodepudi is the **MD & Group CEO of Viyash Scientific Limited since Dec 2025**
- Dr. Hari has **30 years** of extensive experience in the pharmaceutical industry, prior to being appointed as the Group CEO, Dr. Hari was the CEO of Viyash Life Sciences, which he promoted alongside Dr. Sri Hari in 2019
- Under his leadership, Viyash Life Sciences **acquired Symed and Appco** before merging with Sequent Scientific last year
- Prior to starting Viyash Life Sciences, Dr. Hari spent **~20 years with Mylan laboratories** where he held several leadership roles including being the CEO of Mylan India and Global COO of Mylan
- He was responsible for 50+ facilities at Mylan managing a large portfolio of **200+ APIs and 15,000 formulation SKUs**
- Dr. Hari has a hands-on experience in **global supply chain, regulatory, API R&D, quality and commercial operations**
- He has played a **pivotal role** in integrating the two companies and creating a platform which is now set to become a leading integrated pharmaceutical platform with capabilities across front-end, backend, for both human and animal health

1993



Completed PhD in Organic Chemistry from Andhra University

2000-2019



20 years at Mylan – CEO of Mylan India and Global COO of Mylan

2019-2024



Founded Viyash Life Sciences and drove Symed and Appco acquisitions

2024-2025



Played a pivotal role in Sequent-Viyash merger

2026 Onwards

Long way to go ahead – Has grand aspirations to transform Viyash into a leading integrated pharmaceuticals company



2

OUR JOURNEY AND MISSION



**We are an integrated pharmaceutical platform across
animal and human health backed by science and IP**



**IP and
technology
driven company**



**Global presence
across animal
and human
health**



**Backward
integrated
capabilities**



**Front end
presence in
key markets**



**Strong
management
team with
global
experience**

Our Journey



Viyash Life Sciences

Foundation & Early Growth

2019–2020

Founded in February 2019 by Dr Haribabu Bodepudi.

Rapid expansion through acquisitions of Vindhya Pharma and Vandana Life Sciences, and establishment of API R&D infrastructure.

Scale & Expansion

2021

Acquisition of Mylan's API and formulation units in Vizag and Mumbai. Strategic investment by the Carlyle Group.

Acquisition of Symed Labs and Appco Pharma LLC, strengthening global capabilities

Integration & Global Reach

2022–2025

Unified manufacturing operations, expanded R&D to over 200 scientists, filed 175+ patents*, and strengthened global partnerships and regulatory capabilities.

Foundation & Evolution

1985–2013

Originated as Visistha Trades, transitioned into a focused pharmaceutical and animal health company, and rebranded as SeQuent Scientific Limited.

SeQuent Scientific

Global Expansion

2014–2019

Established Alivira as a dedicated animal health brand. Expanded operations across Europe, Latin America, and emerging markets with USFDA veterinary API approvals.

Specialization & Growth

2020–2025

Focused on new geographies and specialized animal healthcare segments, building a strong global manufacturing and distribution network.

Viyash
Scientific Limited

2025 onwards

Both businesses have had their own individual strengths



Sequent Scientific Limited



Strong frontend presence in large animal health markets - Europe, Emerging market and India



Only USFDA approved API facility for animal health in India



Global manufacturing (Europe, LATAM and India)



Diverse product portfolio



API supplier to top pharma innovators

Viyash Life Sciences



Strong manufacturing and R&D setup with 9 USFDA approved sites



Backward integrated to intermediates providing cost competitiveness



IP driven company



US based manufacturing presence for FDF



Presence in 150+ countries



Diverse product portfolio



Niche API capabilities

3

STRENGTHS OF THE COMBINATION

Management Team



**DR. HARIBABU
BODEPUDI**
MD & Group CEO

Ramakant Singani
(Group CFO)

AVV Srinivas
(SVP – R&D Head)

Rajaram Narayanan
(CEO – Animal Health)

Rajkamal Varshney
(SVP – Head of BD)

Alexis Goux
(COO – Animal Health)

BN Srinivas
(Regulatory and Quality)

Dr AJ Reddy
(SVP – Head of SCM)

Dr. Peddanna G
(COO - Appco)

Srinivas Muncheti
(VP – Human Resources)

Yoshita Vora
(Company Secretary)

Sameer Pandit
(CCO - Appco)

Harveen Jindal
(Head of R&D – Animal Health)

16 world class manufacturing facilities



● API ● Formulations

API manufacturing capabilities

Site	Capabilities	Regulatory Approvals
Viyash Scientific Unit I (Viyash-1)	API / HP API	USFDA/ EU-GMP/ PMDA/ TGA/ KFDA/ WHO-GMP
Viyash Scientific Unit II (Viyash-2)	API/ HP API	USFDA/ EU-GMP/ WHO-GMP/ANVISA
Viyash Scientific Unit III (Symed-1)	API	USFDA/ EU-GMP/ WHO-GMP / KFDA/ ANVISA/NIP HUGARY
Viyash Scientific Unit IV (Symed-IV)	API	USFDA/ EU-GMP/ WHO-GMP
Viyash Scientific Unit V (Symed-II)	API	USFDA/ COFEPRIS/ EU-GMP / KFDA/ ANVISA/NIP HUGARY
Viyash Scientific Unit VI (Symed-VI)	API + Advanced Intermediates	USFDA for Advanced Intermediates/ ANVISA for API/ WHO-GMP
Viyash Scientific Unit VII (SV Labs)	Advanced Intermediates	USFDA for Advanced Intermediates
Viyash Scientific Unit VIII (VOPL)	Advanced Intermediates	USFDA for Advanced Intermediates
Viyash Scientific Unit IX (AH) (Mahad)	API	EU-GMP/ COFEPRIS Mexico
Alivira Vizag	API	US FDA/ WHO-Geneva



Formulations manufacturing sites

Site	Type of formulation	Regulatory Approvals
Turkey	Animal	EU GMP/ Turkish GMP
Brazil Unit I	Animal	Brazil GMP
Brazil Unit II	Animal	Brazil GMP
India	Animal	WHO-Geneva
Spain	Animal	EU GMP/ Turkish GMP
USA	Human	USFDA



Formulations manufacturing capabilities



Manufacturing capabilities

Dosage Form	 Spain	 Turkey	 Brazil	 India	 US (HH)
Oral Liquid					
Oral Solution	✓	✓	✓	✓	✓
Liquid for inhalation	✓				
Oral Suspension	✓	✓	✓	✓	✓
Water Soluble Powder	✓		✓	✓	✓
Drug Premix	✓				
Nutritional Feed Add.					
Injectable					
Inj. Solution		✓			
Inj. Suspension		✓			
Pre-Filled Syringes		✓			
Granules for Injection				✓	
Gases					
Aerosols		✓			
Pour On / Spot On		✓			
Disinfectants		✓			
Tablets					✓

Adding a new tablet capacity for animal health


Our R&D landscape



R&D centre	Location	Capabilities / dosage forms	Technologies & infrastructure	R&D members
API R&D	India (Hyderabad, Telangana)	<ul style="list-style-type: none"> • Scalable complex APIs incl. high-potent (OEB 4/5) & cytotoxic; iron-complex, inorganic & complex molecules 	<ul style="list-style-type: none"> • 20+ chemical R&D labs; dedicated process-safety lab; high-end analytical equipment for process dev & validation 	225+
Formulation R&D – Human Health (Viyash / Appco)	India	<ul style="list-style-type: none"> • OSD (Non-Onco) & Onco-Cytotoxic; generics plus complex pharmaceuticals 	<ul style="list-style-type: none"> • Formulation development, analytical method development, tech transfer, QA, regulatory affairs 	60+
Formulation R&D – Animal Health (Alivira)	India, Spain, Turkey	<ul style="list-style-type: none"> • Generic & complex dosage forms — solid, liquid & sterile (oral solutions/suspensions, powders, premixes) 	<ul style="list-style-type: none"> • Formulation development, analytical method development, tech transfer, QA, regulatory filings 	55+

R&D capabilities - Formulations



Dosage Form	 Spain	 Turkey	 Brazil	 India (AH)	 India (HH)
Oral Liquid			✓		
Oral Solution	✓	✓	✓	✓	✓
Liquid for inhalation	✓		✓	✓	
Oral Suspension	✓	✓	✓	✓	✓
Water Soluble Powder	✓		✓	✓	✓
Drug Premix	✓				
Nutritional Feed Add.					
Injectable				✓	
Inj. Solution		✓		✓	
Inj. Suspension		✓		✓	
Pre-Filled Syringes		✓		✓	
Granules for Injection				✓	
Gases					
Aerosols		✓			
Pour On / Spot On		✓		✓	
Disinfectants		✓		✓	
Tablets				✓	✓
High potent formulations					✓



High potent reactions



Best in class analytical center



Process safety lab



Complex molecules like Iron complex

Delivering Results



Human API

60 PATENTS FILED since FY23 with **57 regulatory approvals and 14 patents granted**; **185+ patents** filed till date



Animal API

16 REGULATORY filings since FY23 with **7 REGULATORY** approvals

Animal formulations portfolio



Companion Animals	Commercial	Under development / Pipeline
Number of Products	10+	66+
Global Market Size (\$MN)	NA	~15,400

Farm Animals	Commercial	Under development / Pipeline
Number of Products	130+	21+
Global Market Size (\$MN)	NA	~1,000

API portfolio



Animal API	Commercial	Under development / Pipeline
Number of Products	33	24 (2 first to file launches)
Total Addressable Market Size (\$MN)	NA	~1,600

Human API	Commercial	Under development / Pipeline
Number of Products	60	63 (22 first to file launches)
Total Addressable Market Size (\$MN)	NA	~13,700

Human formulations portfolio




	Commercial	Under development / Pipeline
Number of Molecules	30+	24 (11 first to file launches)
Total Addressable Market Size (\$MN)	NA	~6,200

4

BUSINESS SNAPSHOT

Presence across 150+ countries



Animal formulations

Key European markets, Emerging markets including LATAM and India

API

US, Europe, India, emerging markets and others

Human formulations

US

Key partnerships







An integrated pharmaceutical platform

From two individual growth engines to one powerhouse platform



Revenue (INR MN)



EBITDA (INR MN)



Strong momentum post merger



What did we do to achieve this?



Product and cost optimization



Network synergies-
markets and customers



Corporate and
management integration



SYNERGIES

We are seeing multiple synergies as a result of the combination



Corporate G&A

All corporate and support functions integrated successfully



R&D integration

API R&D has been fully integrated



Procurement

Combined procurement initiated



Product & capacity optimization

Key intermediates moved to internal development
5 major cost improvement AH projects completed



Capacity optimization

Ongoing continuous optimization at manufacturing sites



Revenue Synergies

Leveraging cross-sell opportunities and increasing customer coverage


5

GROWTH DRIVERS

Our business segments



FY26 Revenue Mix



■ Animal formulations ■ API + CDMO ■ Human formulations



Combined platform has global scale needed to capture mega trends in market

Market opportunity	What it takes to win?	Combined platform strength
 <p>Companion Animals Increasing pet ownership and genericization</p>	<ul style="list-style-type: none"> • Market access ✓ • R&D capabilities ✓ • Backward integration ✓ • Manufacturing efficiency and service levels ✓ 	<p>Yes</p>
 <p>Farm Animals Increasing genericization</p>	<ul style="list-style-type: none"> • Portfolio coverage ✓ • Market access ✓ • Cost competitiveness ✓ 	<p>Yes</p>
 <p>API Upcoming patent cliff</p>	<ul style="list-style-type: none"> • Customer access ✓ • Portfolio coverage ✓ • Backward integration and service levels R&D strength ✓ 	<p>Yes</p>
 <p>CDMO Lifecycle management and complex generics</p>	<ul style="list-style-type: none"> • Innovator relationships ✓ • IP driven culture ✓ • ESG and quality standards ✓ 	<p>Yes</p>



Animal formulations

Companion Animals

Farm Animals

New product development, Market expansion, Manufacturing expansion and M&A

Portfolio completion, Geo extension



API & CDMO

Portfolio expansion, Day 1 launch, complex CDMO



Human formulations

API integrated play, complex products including oncology



ANIMAL FORMULATIONS (COMPANION ANIMALS)

Market Opportunity



Companion animal market is accelerating towards genericization


\$22Bn

TODAY



\$32Bn

2030





Increasing pet ownership

1.4bn

Dogs and cats are kept as
pets world-wide

46%

Of EU house
holds own a pet

66%

Of US households
own a pet

Our Focus Markets



	Market	Viyash Present?	Companion animal market size (\$bn)
Phase 1	UK	No	1.1
	France	No	0.9
	Germany	No	0.8
	Italy	Yes	0.8
	Australia	No	0.6
	Canada	No	0.6
	Brazil	Yes	0.5
	Spain	Yes	0.4
	Benelux	Yes	0.2
	Mexico	Yes	0.2
	Rest of Europe	Yes	1.1
	India	Yes	0.2
Phase 2	US	No	10.3



Product Opportunity



Therapy Area	Market size (\$bn) [non-US]	Addressable market of our pipeline (\$bn)
Parasiticides	5.4	4.9
Dermatology	1.1	0.5
Pain management	1.1	0.9
Cardiology	0.4	0.3
Anti-infectives	0.8	0.6
Other therapeutics	1.6	-
Vaccines	2.1	-

Large addressable market -> we are investing in R&D, manufacturing and market access

Bio For Life acquisition in Italy



We have signed an acquisition in Italy aligned with our strategy

01

Provides access to a large companion animal market in Italy

02

Companion animal portfolio (85-90 products) that can be extended to other core markets

03

Launch our global pipeline in Italy; salesforce has 85% vet clinic coverage

04

Strong talent addition in Italy



Our aspiration

\$150-200Mn



Revenue From companion animals



Target by **2032**

Become a top **10** animal health player globally



B

ANIMAL FORMULATIONS (FARM ANIMALS)

Key drivers



Geo Extension

Strong and proven product portfolio which we are registering across all core markets

25+ products to be geo extended

New products

Diverse product portfolio; continuous focus to bridge gaps

20+ new products added in pipeline

New markets

Enter new, large markets where our presence is low

Vietnam, Australia, Canada, Africa, Latam



API + CDMO

Lifecycle management CDMO: Innovator business

Our strengths



Fully Integrated



Quality focused



Cost Efficient



Impeccably compliant

15

Products

\$2.5 Bn

Total market size of existing and pipeline products



Targeting 20%+ growth in the segment

API & CDMO: Specialty and Generics business



Partnership models



Contract manufacturing



Co-investment



R&D and manufacturing

15

Partners

28

Projects

9

First to file projects

\$80 Bn

Market size of all projects

Target to triple (>25%+ CAGR) the business over next 5 years

D

HUMAN FORMULATIONS



Growth levers



Patent cliffs



Integrated oncology play



Large oral solids and liquids market

60+

Products

28

New products

\$4.5 Bn

Market size of products

6


OUR ASPIRATIONS

Our 2032 Aspirations



Revenue

~\$1 Bn



EBITDA

~\$250 Mn



**Companion
Animal revenue**

\$150-200Mn



ROCE

25%+


Disclaimer


- This document has been prepared by Viyash Scientific Limited (“Company”) and contains certain statements that may be deemed to be “forward-looking statements” within the meaning of applicable securities laws. All statements that are not statements of historical fact, including statements relating to the Company’s objectives, plans, strategies, future events, financial performance, projections and expectations, are forward-looking statements.
- The forward- looking statements are based on the Company’s current assumptions, expectations and projections concerning future events and business performance. Forward-looking statements can often be identified by terms such as “anticipate,” “aspire”, “believe,” “expect,” “estimate,” “intend,” “plan,” “project,” “aim,” “target,” “may,” “will,” “should,” and similar expressions.
- Given their nature, forward-looking statements involve risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied in such statements. These factors include, among others:
 - Economic, business and political developments in India and international markets;
 - Changes in laws, regulations, government policies and compliance requirements, particularly those affecting the pharmaceutical industry;
 - Variations in foreign exchange rates, interest rates, inflation and other macroeconomic conditions;
 - The Company’s ability to execute its business strategy, product commercialization and expansion initiatives;
 - Market demand, competitive pressures, pricing trends and industry dynamics;
 - Supply chain, operational or technological disruptions; and
 - Other risks and uncertainties that may impact the Company’s business and financial performance.
- As a result, actual outcomes may differ significantly from those anticipated in any forward-looking statement if one or more of the above risks or uncertainties materialize. No representation or warranty, express or implied, is made with respect to accuracy, completeness or adequacy of information contained in this presentation. Nothing contained in this presentation should be construed as a recommendation or advice to any investor to subscribe for or purchase any securities of the Company. Recipients should conduct their own independent assessment and seek professional advice where appropriate.
- Except as required by applicable law, Viyash Scientific Limited undertakes no obligation to update, revise or publicly release any changes to forward-looking statements contained in this document, whether as a result of new information, future developments or otherwise.
- This document is property of Viyash Scientific Limited and may not be copied, reproduced, distributed or transmitted, in whole or in part, without the prior written consent of the Company.

THANK YOU

Yoshita Vora

Company Secretary

 +91 22 4111 4777

 investorrelations@viyash.com

Abhishek Singhal

Investor Relations Consultant

 abhishek@arunya.co.in

Registered Office: Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India

Websites: www.viyash.com | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: VIYASH

ISIN: INE807F01027